Pandora Report 8.23.2024

This week’s edition of the Pandora Report covers the FDA’s recent approval of updated COVID-19 vaccines, more mpox updates as cases continue to crop up outside of Africa, updates on Russia’s targeting of Ukrainian healthcare facilities, and more.

FDA Approves Updated COVID-19 Vaccines

The Food and Drug Administration (FDA) approved updated COVID-19 vaccines on Thursday, allowing Pfizer and Moderna to begin shipping millions of doses of their updated products. Novavax expects its updated offering to become available soon. As the AP notes, the FDA’s decision came earlier this year than last year amid a summer wave of infections across much of the country.

The same piece explains, “This fall’s vaccine recipe is tailored to a newer branch of omicron descendants. The Pfizer and Moderna shots target a subtype called KP.2 that was common earlier this year. While additional offshoots, particularly KP.3.1.1, now are spreading, they’re closely enough related that the vaccines promise cross-protection. A Pfizer spokesman said the company submitted data to FDA showing its updated vaccine “generates a substantially improved response” against multiple virus subtypes compared to last fall’s vaccine.”

The FDA included in its statement on the approvals: ‘“Vaccination continues to be the cornerstone of COVID-19 prevention,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “These updated vaccines meet the agency’s rigorous, scientific standards for safety, effectiveness, and manufacturing quality. Given waning immunity of the population from previous exposure to the virus and from prior vaccination, we strongly encourage those who are eligible to consider receiving an updated COVID-19 vaccine to provide better protection against currently circulating variants.”’

Mpox Updates

Department of Health and Human Services Releases Statement on US Government Response to Mpox

In response to Africa CDC’s declaration of the current mpox outbreak as a Public Health Emergency of Continental Security and the WHO’s subsequent Public Health Emergency of International Concern declaration, the United States has expressed support for these declarations and pledged to work closely with “African governments, Africa CDC and WHO to ensure an effective response to the current outbreak and to protect the health and lives of people of the region.”

The Department of Health and Human Services emphasized in its statement that, while clade I tends to cause a higher number of severe infections, the Department expects outcomes would be much less severe in the United States than in the Democratic Republic of the Congo (DRC).

The same statement also explains that “CDC has issued an updated Health Alert Network advisory urging clinicians to consider clade I mpox in people who have been in DRC or neighboring countries in the previous 21 days; clinicians are also asked to submit specimens for clade-specific testing for these patients if they have symptoms consistent with mpox. Given the geographic spread of clade I mpox, the U.S. CDC issued an updated Travel Health Notice on Aug. 7, 2024, recommending travelers to DRC and neighboring countries practice enhanced precautions.”

United States Announces Addition Support for Africa’s Mpox Response

The United States Agency for International Development (USAID) announced this week a further $35 million in emergency health assistance in response to the current mpox outbreak in Central and East Africa. USAID said in its press release that “The additional assistance announced today will enable USAID to continue working closely with affected countries, as well as regional and global health partners, to expand support and reduce the impact of this outbreak as it continues to evolve. USAID support includes assistance with surveillance, diagnostics, risk communication and community engagement, infection prevention and control, case management, and vaccination planning and coordination.”

European Centre for Disease Prevention and Control Recommends Enhancing Preparedness 

In a recently prepared risk assessment, the European Centre for Disease Prevention and Control (ECDC) said that it is “highly likely that the EU/EEA will see more imported cases of mpox caused by the clade I virus currently circulating in Africa. However, the likelihood of sustained transmission in Europe is very low provided that imported cases are diagnosed quickly and control measures are implemented.”

Furthermore, “ECDC recommends that public health authorities in the EU/EEA maintain high levels of preparedness planning and awareness raising activities to enable rapid detection and response of any further MPXV clade I cases that may reach Europe. Ensuring effective surveillance, laboratory testing, epidemiological investigation and contact tracing capacities will be vital to detecting cases of MPXV clade I on the continent and activating any response.”

Asia on High Alert Following Case in Thailand

Countries across Asia are sounding the alarm on mpox following Thailand’s confirmation of the first case of mpox clade Ib in Asia in Bangkok this week. The patient, a 66-year-old European, landed in Bangkok on August 14 and was sent to the hospital with mpox symptoms. Thailand’s Department of Disease Control said in a statement “We have monitored 43 people who have been in close contact with the patient and so far they have shown no symptoms, but we must continue monitoring for a total of 21 days.”

In response, China, South Korea, and other countries have announced screening and testing measures for passengers arriving from certain countries. In addition to taking similar measures, Taiwan has also begun stockpiling vaccines and starting targeted immunization campaigns for those at higher risk. South Korea identified Rwanda, Burundi, Uganda, Ethiopia, Central African Republic, Kenya, Congo, and the Democratic Republic of Congo as origin points requiring extra precautions for travelers. Furthermore, the Korea Disease Control and Prevention Agency said it will be monitoring waste from aircraft toilets in addition to distributing mpox information pamphlets at airports.

New Vaccines, Tests on the Way

A growing number of countries are promising vaccine donations in response to the outbreak, explains CIDRAP’s Lisa Schnirring, though the DRC argues they are not doing enough. Agence France-Presse reported this week that French Prime Minister Gabriel Attal announced his country will send 100,000 doses of vaccine to impacted African countries in the coming weeks. However, DRC Health Minister Samuel-Roger Kamba told Politico this week “We would like the EU to pledge more.” Kamba elaborated, saying “As we don’t know yet how the disease will progress, the amount promised by the EU would not allow us to protect our entire population should the disease affect more people.”

Politico explains that “The DRC alone needs 3.5 million doses to respond to the current level of infection, Kamba said, while Jean Kaseya, head of the Africa Centres for Disease Control and Prevention (Africa CDC) has said the continent needs at least 10 million doses.”

An official from the European Commission speaking anonymously told Politico “Nobody’s holding onto stocks that Africa desperately needs” and that the donation made by the Commission was the most the organization could get its hands on. Germany is reportedly considering whether or not to donate any vaccine doses, having given its 117,000 doses of JYNNEOS to the German Army.

Schnirring also explained that Swiss manufacturer Roche “… announced that it is working with its partners to enhance mpox lab capacity worldwide. It is also providing training for labs across Africa at the Roche Scientific Campus in South Africa and at other locations. The company also confirmed that its Cobas mpox PCR test, as well as its research-only test kits, can detect the latest mpox variants.”

Further Reading

World Marks 11th Anniversary of Ghouta Sarin Gas Attack

Wednesday marked the 11th anniversary of the 2013 sarin gas attack in Ghouta, Syria, a suburb of Damascus. In a statement on the anniversary, Mina Rozei, CWC Coalition Coordinator, said “The Syrian government of Bashar al-Assad, which was waging a nationwide counterinsurgency campaign, launched rockets carrying sarin gas warheads against targets in the towns of Zamalka, Ein Tarma, and Irbin in the Ghouta region outside of Damascus. The attack, which was launched in the middle of night when many residents were sleeping, killed an estimated 1,127 people and left almost 6,000 more with respiratory problems.”

Rozei continued, “In the days that followed, international condemnation and the possibility of a U.S. military strike against Syria’s chemical weapons facilities led to an unprecedented U.S.-Russia proposal that called on the Syrian Arab Republic to formally accede to the Chemical Weapons Convention, make a comprehensive declaration of its chemical weapons holdings, and allow for the verified removal and eventual destruction of its chemical weapons facilities and stockpile of more than 1,000 metric tonnes of chemical agent. (See the Arms Control Association’s “Timeline of Syrian Chemical Weapons Activity, 2012-2022” for more details.)”

Read more here.

European Medicines Agency Issues Updated Guidance on Treatment, Prophylaxis for Chemical and Biological Agents

The European Medicines Agency (EMA) recently issued two pieces of updated guidance pertaining to medicines used for treatment or prophylaxis following patient exposure to chemical or biological agents used in terrorist attacks. As highlighted by Regulatory News, the guidance focused on chemical agents “covers general information on emergency treatments such as decontaminating victims and principles of treating symptoms for the purposes of basic life support, and summary information, such as descriptions of clinical symptoms and possible treatments, and the main classes of chemical agents that might be deliberately released.”

Furthermore, “The chemical agents covered by the guidance include blister or vesicant agents, nerve agents, cyanides, lung-damaging agents and pharmaceutically based agents. The list of substances is mainly derived from a list developed by the US Center for Disease Control and Prevention (CDC). The guidance supersedes a previous version issued in April 2003.”

The new guidance on biological agents was prepared in response to a request from the European Commission and “… includes a database of scientific information on pathogenic agents that might be deliberately released and information on the existence of vaccines and other medicines available to prevent or treat their effects.”

World Health Organization Records 1,940 Attacks Against Health Care in Ukraine Since February 2022

On Monday, the WHO confirmed 1,940 attacks on healthcare facilities and personnel have been carried out by Russia in Ukraine since February 2022. In its statement, the WHO said “…we aim to remind the world about one of the biggest ongoing emergencies in the WHO European Region with a grim milestone – 1940 WHO-confirmed attacks on healthcare— the highest number WHO has ever recorded in any humanitarian emergency globally to date. In addition, we are noting new patterns in the progression of the attacks.”

“For over 2.5 years now, 86% of all such attacks have impacted health facilities, with a significant proportion of such attacks involving heavy weapons. Moreover, WHO-verified attacks on health facilities have intensified significantly since December 2023 – occurring on a near-daily basis.”

““In 2024, we are observing a lot of double-tap attacks,” said Dr Jarno Habicht, WHO Representative in Ukraine. “Now we have more shelling of civilian infrastructure than before. We are losing colleagues – healthcare workers, nurses, doctors, paramedics. This year, many more healthcare workers have also been injured than before. According to WHO data, first responders and health transportation are three times more likely to suffer harm from attacks compared to the rest of the healthcare personnel.”’

Read more here.

“First Biolab in South America for Studying World’s Deadliest Viruses is Set to Open”

Meghie Rodrigues recently published this Nature News piece discussing Brazil’s BSL-4 lab-Orion-that is nearing completion of its construction at the Brazilian Center for Research in Energy and Materials. Rodrigues also talked to Biodefense Graduate Program Director Gregory Koblentz, writing in the piece “Another challenge for Orion will be training staff members to work in a type of facility that is new for the region. The facility must also develop a regulatory framework to ensure that risky experiments have oversight from a governing panel, and must install security measures to prevent unauthorized access by people or organizations that might intentionally release pathogens, says Gregory Koblentz, a biodefence specialist at George Mason University and a co-author of the 2023 Global BioLabs report.”

“How U.S. Farms Could Start a Bird Flu Pandemic”

Apoorva Mandavilli discusses how H5N1 continues to plague the US in this piece for the New York Times, explaining in part “Without a sharp pivot in state and federal policies, the bird flu virus that has bedeviled American farms is likely to find a firm foothold among dairy cattle, scientists are warning. And that means bird flu may soon pose a permanent threat to other animals and to people. So far, this virus, H5N1, does not easily infect humans, and the risk to the public remains low. But the longer the virus circulates in cattle, the more chances it gains to acquire the mutations necessary to set off an influenza pandemic.”

“AI and Biosecurity: The Need for Governance”

Bloomfied et al. recently published this Policy Forum piece in Science: “Great benefits to humanity will likely ensue from advances in artificial intelligence (AI) models trained on or capable of meaningfully manipulating substantial quantities of biological data, from speeding up drug and vaccine design to improving crop yields (13). But as with any powerful new technology, such biological models will also pose considerable risks. Because of their general-purpose nature, the same biological model able to design a benign viral vector to deliver gene therapy could be used to design a more pathogenic virus capable of evading vaccine-induced immunity (4). Voluntary commitments among developers to evaluate biological models’ potential dangerous capabilities are meaningful and important but cannot stand alone. We propose that national governments, including the United States, pass legislation and set mandatory rules that will prevent advanced biological models from substantially contributing to large-scale dangers, such as the creation of novel or enhanced pathogens capable of causing major epidemics or even pandemics.”

“Preventing and Controlling Global Antimicrobial Resistance — Implementing a Whole-System Approach”

Don Goldmann, Sowmya Rajan, and Krishna Udayakumar recently published this perspective piece with The New England Journal of Medicine, explaining in part “We recently participated in a public–private collaboration (the Surveillance Partnership to Improve Data for Action on Antimicrobial Resistance [SPIDAAR], funded by Pfizer and the Wellcome Trust) aimed at assisting ministries of health (MOHs) and hospitals in Ghana, Kenya, Malawi, and Uganda in implementing, scaling up, and sustaining improved AMR surveillance capacity. This demonstration project evolved from focused detection of AMR in pathogens targeted by the WHO’s Global Antimicrobial Resistance and Use Surveillance System (GLASS) program2 to include broader efforts to leverage real-time AMR data to improve patient care. SPIDAAR provided insights into the type of integrated system that would be required to address gaps between aspirational national action plans and progress on the ground. The Ugandan MOH’s surveillance-system diagram captures a vision of the high-level systems required for improvement and MOH–hospital coordination (see figure).”

“Five Ways Science is Tackling the Antibiotic Resistance Crisis”

Nature News’ Amber Dance discusses various approaches to combating antibiotic resistance and the threat this issue poses in this piece, writing in part “Hongzhe Sun, a chemical biologist at the University of Hong Kong, says that in his part of the world, “we anticipate maybe the next pandemic will be the crisis of antibiotic resistance”. Indeed, a global crisis is already happening. According to a Lancet study, about 1.27 million deaths worldwide in 2019 could be attributed to drug-resistant infections, making them a leading cause of death1. By 2050, such infections could kill as many as ten million people every year2, according to an expert panel commissioned by the UK government in 2014.”

“Tropical Nights, Burning Eyes: Chloropicrin in Hawaii”

Markus K. Binder discusses the 2017 use of chloropicrin by a criminal gang in Hawaii and lessons learned from the incident in this piece for CBNW. Binder writes in his conclusion “…there is the effective invisibility of criminal actors to the various tools that have been developed to identify and interdict international terrorist operatives, particularly through interception of their communications. Criminal plots frequently have very short cycle times from inception to execution and are unlikely to involve foreign controllers such as those that exposed the 2017 Sydney hydrogen-sulfide plot.”

What We’re Listening to 🎧

Tech Can’t Save Us: Reshaping Biosecurity with Kevin Flyangolts, Founder & CEO of Aclid

“In this week’s episode of Tech Can’t Save Us, hosts Paul David and Maya Dharampal-Hornby are joined by Kevin Flyangolts, Founder & CEO of Aclid.”

“With biotechnology becoming increasingly digital and automated, biosecurity guidelines are constantly changing. Aclid enables end-to-end compliance for gene synthesis providers by automating biosecurity screenings, promoting education in the life science sector, and building trust between companies and customers.”

“Tune into this episode now to hear Kevin discuss how biosecurity concerns have evolved since covid-19, and explain why adaptive regulations, responsible practices, and automated screenings and verifications are the future of biosecurity.”

NEW: BSL4ZNet International Conference

“The Biosafety Level 4 Zoonotic Laboratory Network (BSL4ZNet) is an international group of federal institutions in Australia, Germany, United Kingdom, United States and Canada responsible for high-containment laboratories that allows countries to work together to respond to dangerous zoonotic diseases that spread between animals and people.”

“The 2024 BSL4ZNet International Conference is taking place in September 2024. This year’s theme is “Emerging disease meets innovative science. The working language of the BSL4ZNet is English. The 2024 BSL4ZNet International Conference will be presented in English only.”

“The 2024 BSL4ZNet International Conference includes 4 sessions:

  • Wednesday, September 4: Threats and challenges – Delving into topics such as Highly Pathogenic Avian Influenza (HPAI), Climate-Related Risks, and the nuanced landscape of Science Communication amidst Misinformation/Disinformation Challenges.
  • Wednesday, September 11: Innovation and emerging technologies –  Innovation and Emerging Technologies: Exploring the latest advancements and breakthroughs in the realm of emerging technologies shaping our response to infectious diseases.
  • Wednesday, September 18: Biosecurity and biosafety – Addressing critical issues surrounding biosecurity and biosafety measures, crucial pillars in combating zoonotic diseases
  • Wednesday, September 25: Innovation for BSL4 activities and challenges – Featuring an enlightening panel discussion focusing on innovative approaches to address challenges inherent to BSL4 activities.”

Register for free here.

Safeguarding the Food Supply: Integrating Diverse Risks, Connecting with Consumers, and Protecting Vulnerable Populations – A Workshop

From the National Academies: “On September 4-5, the Food Forum will host a workshop that explores the state of the science around hazard- and risk-based approaches to safeguarding both domestic and global food systems. Workshop presenters will examine nutrition, economic, and equity implications in food safety decision-making, and considerations and strategies for communicating hazard and risk across sectors. The workshop will also include national and international perspectives on risk assessment and tools to mitigate risk, as well as opportunities for the future of risk management and assessment, food safety, and public health.”

Learn more and register for this virtual event here.

NEW: Horizon Fellowship Applications Open

Applications are now open for the 2025 Horizon Fellowship cohort

What do you get?

  • The fellowship program will fund and facilitate placements for 1-2 years in full-time US policy roles at executive branch offices, Congressional offices, and think tanks in Washington, DC.
    • Horizon has placed fellows at the Department of Defense, White House, Department of Commerce, Senate committees, House personal offices and prominent think tanks. You can learn more about past fellows and their placements at Meet our Fellows and Fellow Accomplishments.
  • It also includes ten weeks of remote, part time policy-focused training, mentorship, and an access to an extended network of emerging tech policy professionals.

Who is it for?

  • Entry-level and mid-career roles
  • No prior policy experience is required (but is welcome)
  • Demonstrated interest in emerging technology
  • US citizens, green card holders, or students on OPT
  • Able to start a full time role in Washington DC by Aug 2025
    • Training is remote, so current undergraduate and graduate school students graduating by summer 2025 are eligible

Research shows that great candidates often disqualify themselves too quickly, especially if they are from underrepresented groups. If you are excited about the program but on the fence about whether you are eligible or qualified, we strongly encourage you to apply. The application deadline is August 30th, 2024.

NEW: International Science Reserve, Center for Advanced Preparedness and Threat Response Simulation Launch Serious Game

“The International Science Reserve (ISR), in partnership with the Center for Advanced Preparedness and Threat Response Simulation (CAPTRS), has launched a free, digital game to help scientists and experts worldwide explore and improve their decision-making in public health crisis contexts.”

“In the new game, launched today, players must navigate an evolving and hypothetical public health crisis, evaluating new information that is shared as the game progresses. To simulate real-world situations, players are presented with dynamic information and surveillance data about a pathogen outbreak. In a series of game rounds, they are asked to practice their decision-making skills using data to identify outbreak trends and better prepare for and reduce the public health threat.”  

“The game, the first of a series, fills a major gap in global scientific research planning on crisis preparedness and response. “Serious games” can help experts explore risk and response to situations that could arise, related to climate change adaptation and public health crises.”

“For example, despite lessons from the COVID pandemic, there is currently a slow response to the initial spread to humans of bird flu. More advance experience of scenarios like the digital pathogen game can help accustom policymakers to assessing different sources of scientific information to make decisions, while it can help scientists explore how their research could be prioritized and adapted when most needed.”

Read more here.

Call for Experts-Potential Research Priorities to Inform Readiness and Response to Highly Pathogenic Avian Influenza A (H5N1): A Workshop

From the National Academies: The National Academies is seeking suggestions for experts to participate in a new workshop exploring research priorities to inform readiness and response to the ongoing Highly Pathogenic Avian Influenza (HPAI) A (H5N1) outbreak in the United States. Recognizing the interconnection between people, animals, and their shared environment, the workshop will take a One Health approach to bring together federal government agencies, the academic community, and the private sector, as well as other relevant stakeholders across the health, agriculture, and food safety sectors and will focus primarily on basic science and research questions of specific concern. 

Approximately 8-10 volunteer experts are needed to build a committee for a future workshop and any publications resulting from this activity. Expertise in the following areas is desired:

  • One Health and emerging infectious diseases
  • National, state, and/or local public health and medical readiness and response
  • Epidemiology and surveillance
  • Medical countermeasures (diagnostics, vaccines, therapeutics)
  • Agricultural and veterinary health and sciences
  • Food safety
  • Social sciences, risk communication, and community engagement
  • Modeling, risk assessment, and strategic foresight
  • Regulatory issues

Please submit nominations by August 30, 2024. For any additional questions regarding the forum, please view the project page or email Shalini Singaravelu at SSingaravelu@nas.edu.

Learn more and submit nominations here.

Pandora Report 3.29.2024

This week’s Pandora Report covers the creation of the National Bioeconomy Board, reports of HPAI infections in cattle in multiple states, a new PBS public health docu series, new professional opportunities, and more.

Biodefense PhD Student Presents Research at 2024 Preparedness Summit

Kimberly Ma, a PhD student in the Biodefense Graduate Program, recently presented her research at the 2024 Preparedness Summit in Cleveland. She told the Pandora Report a bit about it, saying “This week, I had the fortune to once again attend the Preparedness Summit in Cleveland. This was my third time attending, but this time, instead of as a public health worker, I came in my personal and Ph.D. student capacity to present my poster “Bioterrorism Risk Communications: Where Are We Now?” and a session born out of a peer-reviewed article in Health Security that I wrote with preparedness leaders across the country, “Reimagining Incident Management Systems for Public Health Responses.”

Read more about her experience here.

White House Launches National Bioeconomy Board

The White House recently announced that it is launching the National Bioeconomy Board to help manage the economic impact of biotechnology and biomanufacturing. In a blog post for the Office of Science and Technology Policy (OSTP), Sarah Glaven, OSTP’s Principal Assistant Director for Biotechnology and Biomanufacturing, Industrial Innovation, explained “Biotechnology harnesses the power of biology to create new services and products, which provide opportunities to grow the U.S. economy and workforce and improve the quality of our lives and the environment. This week, the Biden-Harris Administration took an important step toward realizing the potential of biotechnology for the U.S. economy by launching the National Bioeconomy Board. The Board will work with partners across the public and private sectors to advance societal well-being, national security, sustainability, economic productivity, and competitiveness through biotechnology and biomanufacturing.”

The same blog explains that “The National Bioeconomy Board is co-chaired by the White House Office of Science and Technology Policy (OSTP), the Department of Commerce (DOC), and the Department of Defense. The Board also includes representatives from nine additional federal departments and agencies: The State Department, National Science Foundation, Department of Homeland Security, Department of Health and Human Services, National Aeronautics and Space Administration (NASA), Department of Justice, Department of Energy, Department of Agriculture (USDA) and the Office of the Director of National Intelligence. Board members represent the variety of biotechnology and biomanufacturing stakeholders across the federal government, including departments and agencies that promote economic development, sponsor fundamental research, facilitate technology commercialization, focus on safety and security, and engage in workforce training.”

The creation of the Board accompanies the Inflation Reduction Act, Bipartisan Infrastructure Law, and CHIPS and Science Act as part of the administration’s Investing in America agenda, which aims “…to revitalize U.S. manufacturing, bolster national security, and build a sustainable economy for all Americans. The strategy is catalyzing investment in the bioeconomy: since the start of the Biden-Harris Administration, private companies have announced over $20 billion in biomanufacturing investments.”

Bird Flu Detected in Texas, Kansas, and New Mexico

On March 25, USDA officials reported cows in Texas, Kansas, and New Mexico were sick with what is presumed to be the H5N1 influenza virus that has already killed millions of birds. These cattle infections are spoiling milk and causing disease in older animals, with some impacted farms also reporting that dead birds have been discovered on their property, potentially explaining the source of the cattle infections. A case of highly pathogenic avian influenza was detected in a Minnesotan goat earlier this month, marking the first US livestock case of a disease that very rarely spreads between mammalian species.

An article for Science News explains that “Gregory Gray, an epidemiologist at the University of Texas Medical Branch, calls the new detections in cows across multiple states a “worrisome” development because it may signal this bird flu strain is spreading directly between cattle, instead of via birds, and has mutated in ways that could allow it to better infect people. But preliminary studies on the affected cows show no signs that the virus has changed, the National Veterinary Services Laboratories said in a statement yesterday.”

The threat to the public is still considered low, though human cases have been reported recently in Cambodia and Vietnam.

“National Road Map to Invest in RNA Science and Biotechnology”

This write-up from Global Biodefense breaks down a recent report from the National Academies that “charts a course for developing technologies and infrastructure that would enable the determination of any epitranscriptome of scientific and public interest.” The write-up explains in part “Currently, without knowing the exact composition of all RNA molecules that derive from each gene, researchers’ ability to understand the molecular underpinnings of health and disease is severely limited. Every cell in every organism has a different set of modified RNA molecules that make up its epitranscriptome. Epitranscriptomes are constantly changing as cells develop and respond to their environment. RNA can act as an indicator about a patient’s health, is a potential pathway for delivering treatments, and provides real-time information about what is changing and happening in an organism.”

“Charting a Future for Sequencing RNA and Its Modifications: A New Era for Biology and Medicine”

From the National Academies: “Concerted efforts to deepen understanding of RNA modifications and their role in living systems hold the potential to advance human health, improve crop yields, and address other pressing societal challenges. RNA, which carries the information encoded by DNA to the places where it is needed, is amazingly diverse and dynamic. RNA is processed and modified through natural biological pathways, giving rise to hundreds, in some cases thousands, of distinct RNA molecules for each gene, thereby diversifying genetic information. RNA modifications are known to be pivotal players in nearly all biological processes, and their dysregulation has been implicated in a wide range of human diseases and disorders. Yet, our knowledge of RNA modifications remains incomplete, hindered by current technological limitations. Existing methods cannot discover all RNA modifications, let alone comprehensively sequence them on every RNA molecule. Nonetheless, what is known about RNA modifications has already been leveraged in the development of vaccines that helped saved millions of lives worldwide during the COVID-19 pandemic. RNA modifications also have applications beyond health, for example, enhancing agricultural productivity.”

Charting a Future for Sequencing RNA and Its Modifications: A New Era for Biology and Medicine calls for a focused, large-scale effort to accelerate technological innovation to harness the full potential of RNA modifications to address pressing societal challenges in health, agriculture, and beyond. This report assesses the scientific and technological breakthroughs, workforce, and infrastructure needs to sequence RNA and its modifications, and ultimately understand the roles RNA modifications play in biological processes and disease. It proposes a roadmap of innovation that will make it possible for any RNA from any biological system to be sequenced end-to-end with all of its modifications – a capability that could lead to more personalized and targeted treatments and instigate transformative changes across various sectors beyond health and medicine.”

“Future State of Smallpox Medical Countermeasures”

From the National Academies: “At the request of the Administration for Strategic Preparedness and Response, the National Academies convened a committee to examine lessons learned from the COVID-19 pandemic and mpox multi-country outbreak to inform an evaluation of the state of smallpox research, development, and stockpiling of medical countermeasures (MCM). In the resulting report, the committee presents findings and conclusions that may inform U.S. Government investment decisions in smallpox MCM readiness, as well as the official U.S. position on the disposition of live viral collections at future World Health Assembly meetings.”

Bonus: Read Mary Van Beusekom’s discussion of this report for CIDRAP

“Ten Years of High-Consequence Pathogens—Research Gains, Readiness Gaps, and Future Goals”

McQuiston, Montgomery, and Hutson recently published this commentary article in Emerging Infectious Diseases, explaining in part: “Despite successful variola virus eradication, orthopoxviruses remain high-consequence pathogens that create complex control challenges. During 2014–2024, reports of mpox caused by MPXV surged in regions where the virus is enzootic. During 2017–2022, increased reports of mpox in Nigeria initially raised little concern, even though mpox was diagnosed in occasional travelers from Nigeria who had no history of animal contact (9). In May 2022, MPXV clade II began circulating person-to-person globally, primarily through sexual contact among gay, bisexual, and other men who have sex with men (10). Thanks to smallpox preparedness work performed by the US Centers for Disease Control and Prevention and other partners, regulatory agency-approved diagnostics, the JYNNEOS vaccine (https://www.jynneos.comExternal Link), and TPOXX therapeutic agent (SIGA Technologies, https://www.siga.comExternal Link) were available in some countries; however, limited early supplies of the JYNNEOS vaccine and lack of licensure in some countries meant the vaccine was not accessible to all persons at risk for MPXV exposure. Before the global mpox outbreak, no real-world efficacy data for TPOXX was available; clinical trials are ongoing. After the mpox outbreak peak in 2022, MPXV has continued to circulate at low levels through 2024; since 2022, >90,000 cases have been reported worldwide (11). Since 2023, similar surveillance signals have been seen in DRC with MPXV clade I (12), raising concerns for another global mpox outbreak caused by a more lethal virus clade.”

“The Impact of Vaccines and Behavior on US Cumulative Deaths from COVID-19”

This Brookings summary of a paper authored by Andrew Atkeson and Stephen Kissler offers insight into potential approaches to addressing shortfalls in how the federal government manages massive amounts of public health data and the importance of both vaccines and behavioral changes in reducing overall COVID-19 deaths. The summary explains in part, “However, the authors write in “The Impact of Vaccines and Behavior on U.S. Cumulative Deaths from COVID-19,” the ad hoc effort’s effectiveness came as a surprise. Public health officials could not precisely target mitigation because they lacked precise information on the routes and mechanisms of the disease’s transmission.”

“Awaiting a Decision On New Research Regulations, Scientists Pen Dueling Articles to Shape ‘Gain-of-Function’ Policies”

Matt Field breaks down the scientific community’s responses to recommendations made by the National Science Advisory Board for Biosecurity last year in this article for The Bulletin of the Atomic Scientists, writing in part “As they await a decision on policies for potential pandemic pathogen research, dueling camps of scientists have emerged, weighing in through a journal article, responses to the article, and even responses to the responses. Those camps are seeking to undercut or boost the advisory recommendations developed in the wake of the COVID pandemic—and to bolster or diminish the suspicion that a lab accident could have caused it.”

“Ecological Countermeasures to Prevent Pathogen Spillover and Subsequent Pandemics”

Plowright et al. recently published this article in Nature: “Substantial global attention is focused on how to reduce the risk of future pandemics. Reducing this risk requires investment in prevention, preparedness, and response. Although preparedness and response have received significant focus, prevention, especially the prevention of zoonotic spillover, remains largely absent from global conversations. This oversight is due in part to the lack of a clear definition of prevention and lack of guidance on how to achieve it. To address this gap, we elucidate the mechanisms linking environmental change and zoonotic spillover using spillover of viruses from bats as a case study. We identify ecological interventions that can disrupt these spillover mechanisms and propose policy frameworks for their implementation. Recognizing that pandemics originate in ecological systems, we advocate for integrating ecological approaches alongside biomedical approaches in a comprehensive and balanced pandemic prevention strategy.”

“To Prevent Global Catastrophe, Governments Must First Admit There’s a Problem”

Rumtin Sepasspour and Courtney Tee recently published this piece in The Bulletin of the Atomic Scientists discussing political inaction on perceived risks of global catastrophe, writing in part “To properly prevent and prepare for the risk, governments must admit there’s a problem. Such an admission can only come with proper effort to assess and monitor global catastrophic risk, develop potential future scenarios, build and analyze intelligence, and invest in scientific and technical expertise.”

“Bibliometric Analysis of China’s Non-Therapeutic Brain-Computer Interface Research: Alternate Paths to Cognitive Augmentation and Control”

From CSET: “China’s brain-computer interface research has two dimensions. Besides its usual applications in neuropathology, China is extending the benefits of BCI to the general population, aiming at enhanced cognition and a “merger” of natural and artificial intelligence. This report, authored in collaboration with researchers from the Department of War Studies at King’s College London uses bibliometric analysis and expert assessment of technical documents to evaluate China’s BCI, and conclude that the research is on track to achieve its targets.”

“Russia’s Increasing Illegal Chemical Weapons Usage in Ukraine”

Tim Mak, Alessandra Hay, and Oksana Ostapchuk cover an interview with a survivor of a 2013 sarin gas attack in Syria and how inaction afterward has emboldened leaders like Vladimir Putin to use these weapons more frequently in this piece for The Counteroffensive. Warning: this article does contain graphic content.

“VX Nerve Agent Incident: Lessons Learned, Best Practices, and the Challenges Ahead”

From CBNW Magazine: “The 2017 VX nerve agent incident in Malaysia stands as a poignant demonstration of the catastrophic capability of asymmetrical chemical weapon threats, underscoring the critical necessity for increased attentiveness in averting and addressing such risks, writes Dr. Raja Subramanian.”

“CHEMEX Africa 2023: Interview with H.E. Ambassador Salima Abdelhak, P.R. of Algeria to OPCW”

From CBNW Magazine: “Taking place from September 23 to October 5, 2023, in the Algerian capital of Algiers, CHEMEX Africa was the first ever large-scale chemical emergency response exercise for African countries organized by the OPCW. CBNW Magazine Editor Patrick Norén spoke to the Permanent Representative (P.R.) of Algeria to the OPCW, H.E. Ambassador Salima Abdelhak, about the exercise and Algeria’s commitment to implementing the Chemical Weapons Convention (CWC). A full article on CHEMEX Africa containing extracts from this interview will be published in April.”

Read here.

What We’re Watching 🍿

The Invisible Shield

A new four-part docu series from PBS, “The Invisible Shield examines how public health makes modern life possible, but it is underfunded, undervalued and misunderstood putting our health at risk.”

Strem this series here.

NEW: The Future of U.S. Bulk Data Sharing and Use

From BIO-ISAC: “On February 28, 2024, the White House issued an Executive Order on Preventing Access to Americans’ Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern.”

“The Executive Order (EO) seeks to secure sensitive data from being shared with individuals, companies, and investors outside the US, particularly those connected to countries that may harm the US or its people.”

“The Department of Justice (DOJ) also issued a fact sheet and advanced notice of proposed rulemaking (ANPRM) regarding the proposed guidance and implementation strategies in the text.

  • What does this mean for the bioeconomy?
  • How has industry responded to this call for action?
  • What does this mean for the future of data sharing collaborations and research?”

“This collaborative discussion, with the BIO-ISAC community and representatives from the U.S. Department of Justice, will share an overview of the EO and ANPRM, explore the intent and efforts connected to these actions, and offer a Q&A session to review specific examples, pinch points, and ideas.”

This discussion will take place on April 5 at 12 pm EST. Learn more and register here.

NEW: EBRC & NIST Sequence Screening Virtual Workshop #1

From ERBC: “Synthetic DNA enables life sciences research that can be applied to pressing societal challenges across many sectors, but could also be used in the development of biological parts, systems, or organisms that cause great harm to human, public, or environmental health. Many companies that produce and sell synthetic DNA screen ordered sequences to prevent customers from inappropriately accessing Sequences of Concern (SOCs). This project aims to improve DNA synthesis screening by enabling the development of better tools and mechanisms for screening performance evaluation.”

“This will be the first workshop in the series. Additional virtual workshops will be held over the next six months, with an in-person meeting to be held in the fall. More details to come.”

This event will take place on April 9 at 1 pm EST. Learn more and register here.

NEW: The Advancing Threat Agnostic Biodefense Webinar Series

From PNNL: “Join us as we welcome Patrick Chain, scientist at Los Alamos National Laboratory (LANL). His talk, titled “Toward Pathogen-Agnostic Detection: Advances and Challenges in Shotgun Sequencing-Based Biosurveillance” will be Tuesday, April 16, at noon PT.”

“Patrick Chain leads the Metagenomics Applications, Bioinformatics, and Analytics Teams in the Bioscience Division at LANL, while also co-managing the Division’s Genomics Program. His team pioneers innovative algorithms and methods in bioinformatics and metagenomics, applying them to various research areas such as organism detection, sample characterization, and fundamental research across different ‘biomes’. With a background including a B.Sc. and M.Sc. from McMaster University and a Ph.D. from Michigan State University, Chain brings a wealth of expertise to the field.”

“The Advancing Threat Agnostic Biodefense Webinar Series brings together like-minded science and policy members of the biodefense community to discuss relevant research activities as well as barriers and enablers of a threat agnostic approach. The webinar series is hosted by the Nuclear, Chemical, and Biological Technology Division.”

Register here.

Artificial Intelligence and Automated Laboratories for Biotechnology: Leveraging Opportunities and Mitigating Risks

From the National Academies’ Board on Life Sciences: “Please join us April 3-4, 2024 for a hybrid workshop on the opportunities and mitigation of risks of the use of artificial intelligence and automated laboratories (i.e., self-driving labs) for biotechnology.”

“The workshop will consider opportunities to leverage AI and laboratory automation capabilities for discovery and development, explore methods and approaches to identify, track, and forecast the domestic and international development of such technologies, and convene experts across sectors to highlight recent advances and explore implications for the development and use of these technologies.”

Learn more and register here.

Launch of the 2024 National Blueprint on Biodefense

From the Bipartisan Commission on Biodefense: “On the 10th anniversary of its inception, the Bipartisan Commission on Biodefense will release its 2024 National Blueprint on Biodefense: Immediate Action Needed to Defend Against Biological Threats.”

“Please join us for this momentous event at the Congressional Auditorium, Capitol Visitor Center, on April 17th at 4:30pm.”

“The Bipartisan Commission on Biodefense (formerly the Blue Ribbon Study Panel on Biodefense) was established in 2014 to provide a comprehensive assessment of the state of United States biodefense efforts and to issue recommendations that foster change.  Subsequently, the Commission has briefed White House Administrations (including then Vice President Biden); testified before Congress; convened numerous meetings with experts; released 12 reports; produced the graphic novel Germ Warfare; and mobilized biodefense conversations and actions in the private and public sectors.”

Learn more and register here.

Addressing the Challenges Posed by Chemical and Biological Weapons: Intensive Online Introductory Course for Students of Technical Disciplines

“SIPRI and the European Union Non-Proliferation and Disarmament Consortium (EUNPDC) invite graduate and postgraduate students of the technical or natural science disciplines to apply for an intensive online introductory course on chemical and biological weapons—their proliferation, the efforts to eliminate them, the various mechanisms used to control their spread—and endeavours underway to reduce the risk of chemical or biological agents in terrorist attacks. The course will take place online, during four half-days on 2831 May 2024, 14:00 to 18:00 Central European Summer Time (CEST).”

“The course will cover the fundamentals of chemical and biological weapons as well as of missiles and other means of delivery; the history of chemical and biological warfare; the evolution of international norms against these weapons; the threats associated with potential terrorist uses of chemical and biological material; bioweapons and other related scientific advances; the current challenges posed by chemical weapons; arms control treaties; and mechanisms to curb the spread of dangerous substances, including export controls.”

“The course will also discuss the role of the EU institutions and industry to address the challenges mentioned above. The course will be instructed by renowned experts on non-proliferation, arms control, disarmament, export controls, verification and related subjects from SIPRI, other European research centres, think tanks and international organizations.”

Learn more and apply here.

Registration for GHS 2024 Now Open

Registration is now open for the Global Health Security 2024 conference in Sydney, Australia. This iteration will take place 18-21 June, 2024. The call for abstracts is also still open. “The mission of the Global Health Security conference is to provide a forum where leaders, researchers, policy-makers, and representatives from government, international organisations, civil society, and private industry from around the world can engage with each other, review the latest research and policy innovations, and agree solutions for making the world safer and healthier. To that end, our mission is to help foster a genuinely multidisciplinary community of practice that is committed to working collaboratively to enhance global health security and eliminate disease, irrespective of its origin or source.”

SBA.3 International Synthetic Biology, and Biosecurity Conference in Africa

“Join us for the SBA.3 International Synthetic Biology and Biosecurity Conference in Africa, a groundbreaking event that brings together experts, researchers, and enthusiasts in the field of synthetic biology. This in-person conference will take place at the Laico Regency Hotel from Wed, Jul 17, 2024 to Friday, Jul 19, 2024.”

“Get ready to dive into the exciting world of synthetic biology and explore its potential applications in Africa. From cutting-edge research to innovative solutions, this conference offers a unique opportunity to learn, network, and collaborate with like-minded individuals.”

“Discover the latest advancements, trends, and challenges in synthetic biology through engaging keynote speeches, interactive workshops, and thought-provoking panel discussions. Immerse yourself in a vibrant atmosphere where ideas flow freely and new connections are made.”

“Whether you’re a seasoned professional or just starting your journey in synthetic biology, this conference provides a platform to expand your knowledge, exchange ideas, and contribute to the growth of the field in Africa.”

“Don’t miss out on this extraordinary event that promises to shape the future of synthetic biology and biosecurity in Africa. Mark your calendars and join us at the SBA.3 International Synthetic Biology and Biosecurity Conference in Africa!”

Learn more and register here.

Job Announcement: George Mason University, Research Faculty, Infectious Diseases

“The Institute for Biohealth Innovation harnesses the collective talent of more than 300 GMU faculty and staff and thousands of students across 34 academic departments. The IBI connects Mason researchers with potential collaborators, both within the university and externally, to take on some of biohealth’s biggest challenges.”

“The Biomedical Research Lab (BRL), is a core facility overseen by the Institute. The 52,000 square-foot regional biocontainment laboratory (RBL) was established in 2010 as one of 12 NIAID-funded RBLs to support infectious disease research and foster collaborations with other national and global laboratories. It operates as a central core facility to advance research and develop novel diagnostics, therapeutics, and vaccines against viral and bacterial infectious agents by a diverse population of internal and external investigators. The facility is capable of housing multiple species and has a variety of established animal models, with an emphasis on aerosolized exposures. The BRL is fully approved and licensed for work by the CDC and USDA and is accredited by AAALAC.”

“The research faculty will join a collaborative team that works on bacterial or viral pathogens relevant to human and animal disease. The research foci are within broad fields including but not limited to immunology and immunity in disease, host-pathogen interactions, cellular microbiology, biochemistry, animal imaging and pathology, aerobiology, and countermeasure development (diagnostics, vaccines, and therapeutics). The incumbent will work with a diverse team of internal and external investigators including faculty, postdoctoral fellows, undergraduate and graduate students, and industry professionals. The incumbent will be responsible for conducting research, providing training and mentorship, disseminating findings, and contributing to grant proposals to advance infectious disease research and countermeasure development.”

Learn more and apply here.

CEPI Calls for Experts to Join Its Scientific Advisory Committee

From CEPI: “CEPI’s call for new individuals to join its Scientific Advisory Committee, or SAC —an external expert group providing guidance and recommendations to CEPI on R&D programmes and broader outbreak response efforts—is now open through 9 April 2024.”

“CEPI is recruiting global health professionals with extensive experience across relevant scientific and product development disciplines to join its SAC, and is particularly interested in applicants from Latin America and Africa; female applicants are especially encouraged to apply.

“Successful applicants’ scientific input, guidance and challenge will be critical in the continued implementation of the CEPI 2.0 strategy, which aims to accelerate the development of vaccines and other biological countermeasures to tackle emerging infectious diseases and enhance global preparedness for future threats.”

“New members’ terms will last three years, starting in June 2024, with the first face-to-face meeting taking place in Rio de Janeiro from 31 July to 1 August. Virtual participation will be made available for anyone unable to travel at this time.”

“Interested individuals can apply using our online form linked here.